This technology is a shortened version of cell-penetrating, dominant-negative peptides of ATF5, CEBPB, CEBPD for cancer treatment.

The Technology: Short cell-penetrating effective inhibitors to suppress cancer survival.

This technology describes truncated versions of cell-penetrating, dominant-negative peptides of human ATF5, CEBPB, CEBPD to suppress cancer survival.

Unmet Need: Translational murine models for the investigation of angioimmunoblastic T-cell lymphoma.

“RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis.

This technology is a murine model of angioimmunoblastic T-cell lymphoma with Rhoa G17V expression, which recapitulates the features of human disease for further study and therapeutic development.

“Regulation of Ferroptotic Cancer Cell Death by GPX4” Cell.

Ferroptosis is an iron-dependent form of regulated cell death that has been implicated in various diseases such as Alzheimer’s and many types of cancer.

Ferroptosis is an iron-dependent form of regulated cell death that has been implicated in various diseases such as Alzheimer’s and many types of cancer.

This technology describes the synthesis and characterization of small molecule NT5C2 inhibitors for the treatment of relapsed and chemotherapy-resistant acute lymphoblastic leukemia (ALL) and T-cell acute lymphoblastic leukemia (T-ALL).

Unmet Need: Targeted therapies for aggressive, relapsed blood cancers.

“Structure and mechanisms of NT5C2 mutations driving thiopurine resistance in relapsed lymphoblastic leukemia” Cancer Cell.